Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors

被引：1

作者：

Glaeske, Sarah ^{[1
]}

Huebner, Franziska ^{[1
]}

Anurin, Anna ^{[1
]}

Janzer, Andreas ^{[1
]}

Zitzmann-Kolbe, Sabine ^{[1
]}

Paul, Juliane ^{[1
]}

Glaeske, Katja ^{[1
]}

Berndt, Sandra ^{[1
]}

Mumberg, Dominik ^{[1
]}

Gorjanacz, Matyas ^{[1
]}

Ziegelbauer, Karl ^{[1
]}

Kreft, Bertolt ^{[1
]}

Liu, Ningshu ^{[1
]}

机构：

[1] Bayer AG, Berlin, Germany

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-123

引用

页数：2

共 50 条

[21] ANTI-TUMOR ACTIVITY OF DUAL PI3K/MTOR INHIBITORS PF-04691502 AND PF-05212384 IN GLIOBLASTOMA STEM-LIKE CELLS WITH DIFFERENTIAL PI3K PATHWAY ACTIVATION
Tanaka, Shota
Klofas, Lindsay K.
Wakimoto, Hiroaki
Borger, Darrell R.
Iafrate, A. J.
Batchelor, Tracy T.
Chi, Andrew S.
NEURO-ONCOLOGY, 2012, 14 : 26 - 26
[22] PI3K inhibition is necessary and sufficient to induce an anti-angiogenic response in vivo based on suppression of tumor vascular structure
Sampath, D.
Cao, T.
Oeh, J.
Barck, K. H.
Reslan, H. B.
Wyatt, S.
Ungersma, S.
Koeppen, H.
Friedman, L. S.
Carano, R. A. D.
EJC SUPPLEMENTS, 2010, 8 (07): : 150 - 150
[23] Dual inhibition of PI3K and Erk1/2 shows synergy and efficacy in human tumor cells, either by using drug combinations or novel dual PI3K/Erk inhibitors
Seipelt, Irene
Gerlach, Matthias
Blumenstein, Lars
Mueller, Gilbert
Guenther, Eckhard
Engel, Juergen
Teifel, Michael
CANCER RESEARCH, 2012, 72
[24] Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
Ma, Yixuan
Schulz, Benjamin
Trakooljul, Nares
Al Ammar, Moosheer
Sekora, Anett
Sender, Sina
Hadlich, Frieder
Zechner, Dietmar
Weiss, Frank Ulrich
Lerch, Markus M.
Jaster, Robert
Junghanss, Christian
Escobar, Hugo Murua
CANCERS, 2022, 14 (18)
[25] Differentiation of PI3K/Akt/mTOR inhibition in cancer models using dual dissociative TORC1/TORC2 (P529), single dissociative TORC1 (rapalogs) and catalytic inhibitors (PI3K/Akt, PI3K/mTOR)
Sherris, David
Dennis, Philip A.
Wilson, Willie, III
Kawabata, Shigeru
Yu, Chunrong
Gravina, Giovanni Luca
Mancini, Andrea
Festuccia, Claudio
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
[26] The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt
Regmi, Sushil C.
Park, Su Young
Kim, Seung Joo
Banskota, Suhrid
Shah, Sajita
Kim, Dong-Hee
Kim, Jung-Ae
PLOS ONE, 2015, 10 (11):
[27] The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line
Taghiloo, Saeid
Norozi, Saeid
Asgarian-Omran, Hossein
IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2022, 21 (02) : 178 - 188
[28] Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity
Jinan Wang
Fangfang Wang
Zhengtao Xiao
Guowen Sheng
Yan Li
Yonghua Wang
Journal of Molecular Modeling, 2012, 18 : 2943 - 2958
[29] Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity
Wang, Jinan
Wang, Fangfang
Xiao, Zhengtao
Sheng, Guowen
Li, Yan
Wang, Yonghua
JOURNAL OF MOLECULAR MODELING, 2012, 18 (07) : 2943 - 2958
[30] PI3K coupled to PARP inhibition demonstrates synergistic anti-tumor activity in endometrioid endometrial cancer patient derived xenografts
Hall, T. R.
DiGloria, C. M.
Kim, M.
Zhang, L.
Foster, R.
Growdon, W. B.
Rueda, B. R.
GYNECOLOGIC ONCOLOGY, 2015, 137 : 65 - 65

← 1 2 3 4 5 →